New drug combo aims to shrink tough nasal tumors before surgery

NCT ID NCT07616141

First seen Jun 03, 2026 · Last updated Jun 16, 2026 · Updated 6 times

Summary

This study tests whether giving a targeted therapy (anlotinib) plus chemotherapy (epirubicin) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma (T4 stage). About 76 participants will receive the drug combination, then surgery and radiation. The main goal is to see if this approach increases the chance of living without cancer returning for 3 years, compared to standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, 200031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, 266000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510630, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100053, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.